Trial Profile
An open-label, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due to Alpha1-Proteinase Inhibitor Deficiency who completed Clinical Study CE1226_4001
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2018
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Emphysema
- Focus Therapeutic Use
- Acronyms RAPID Extension trial
- Sponsors CSL Behring
- 13 Sep 2018 According to a CSL Behring media release, results of the subgroup analysis of the RAPID trial programme will be presented at the 28th International Congress of the European Respiratory Society (ERS).
- 24 May 2017 Results Post-Hoc Analysis of the RAPID/RAPID Extension Trialpresented at the 113th International Conference of the American Thoracic Society
- 02 Dec 2016 Data from this trial published in the Lancet Respiratory Medicine, as per a CSL Behring media release.